How Purdue’s ‘one-two’ punch fuelled the market for opioidsAccused of exaggerating the benefits of OxyContin, the company’s owners had a bigger share than realisedPurdue Pharma's 'one-two' punchWhat next for the Sacklers? A pharma dynasty under siegeAn investigation into the unfolding scandal of a company accused of fuelling America’s opioid crisisBillionaire Sackler family owns second opioid drugmakerPurdue owners set up Rhodes Pharma after criminal charges in 2007Opioid billionaire granted patent for addiction treatmentPurdue owner Richard Sackler listed as inventor of drug to wean addicts off painkillers
How Purdue’s ‘one-two’ punch fuelled the market for opioidsAccused of exaggerating the benefits of OxyContin, the company’s owners had a bigger share than realisedPurdue Pharma's 'one-two' punchWhat next for the Sacklers? A pharma dynasty under siegeAn investigation into the unfolding scandal of a company accused of fuelling America’s opioid crisisBillionaire Sackler family owns second opioid drugmakerPurdue owners set up Rhodes Pharma after criminal charges in 2007Opioid billionaire granted patent for addiction treatmentPurdue owner Richard Sackler listed as inventor of drug to wean addicts off painkillers
